| Molecular Formula | C18H18N4 |
| Molar Mass | 290.36 |
| Density | 1.229±0.06 g/cm3(Predicted) |
| Melting Point | 192-194℃ (methanol ) |
| Boling Point | 493.2±35.0 °C(Predicted) |
| Solubility | DMSO: 28 mg/mL (96.4 mM)Ethanol: <1 mg/mL( < 1 mg/ml refers to the product slightly soluble or insoluble) |
| Appearance | powder |
| Color | white to tan |
| pKa | 6.55±0.10(Predicted) |
| Storage Condition | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
| Use | WZ811 is an orally active, highly competitive CXCR4 agonist. WZ811 effectively inhibited CXCR4/SDF-1 (also known as CXCL12) -mediated cAMP level regulation (EC50=1.2 nM) and SDF-1-induced stromal gel invasion (EC50=5.2 nM) in cells. |
| Target | CXCR4 |
| In vitro study | WZ811 is a highly potent, competitive CXCR4 antagonist. WZ811, at doses as low as a few nanomolar, was effective in counteracting the SDF-1 reduction in cAMP. WZ811 inhibited SDF-1 mediated invasion with an EC50 of 5.2 nM. |
| Hazard Symbols | Xn - Harmful![]() |
| Risk Codes | R22 - Harmful if swallowed R36/37/38 - Irritating to eyes, respiratory system and skin. |
| Safety Description | 26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
| WGK Germany | 3 |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 3.444 ml | 17.22 ml | 34.44 ml |
| 5 mM | 0.689 ml | 3.444 ml | 6.888 ml |
| 10 mM | 0.344 ml | 1.722 ml | 3.444 ml |
| 5 mM | 0.069 ml | 0.344 ml | 0.689 ml |
| biological activity | WZ811 is an efficient, competitive CXCR4 antagonist with EC50 of 0.3 nM. |
| in vitro studies | WZ811 is a highly effective, competitive CXCR4 antagonist. WZ811 effectively counteracts SDF-1 reduction in cAMP at doses as low as a few nanomoles. WZ811 inhibits SDF-1-mediated invasion with EC50 of 5.2 nM. |